title: Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.
abstract: Malignant astrocytomas, which are highly invasive, vascular neoplasms, compose the majority of nervous system tumors in humans. Elevated expression of fibroblast growth factors (FGFs) in astrocytomas has implicated the FGF family of mitogens in the initiation and progression of astrocyte-derived tumors. In this study, we demonstrated that human astrocytomas undergo parallel changes in FGF-receptor (FGFR) expression during their progression from a benign to a malignant phenotype. FGFR type 2 (BEK) expression was abundant in normal white matter and in all low-grade astrocytomas but was not seen in malignant astrocytomas. Conversely, FGFR type 1 (FLG) expression was absent or barely detectable in normal white matter but was significantly elevated in malignant astrocytomas. Malignant astrocytomas also expressed an alternatively spliced form of FGFR-1 (FGFR-1 beta) containing two immunoglobulin-like disulfide loops, whereas normal human adult and fetal brains expressed a receptor form (FGFR-1 alpha) containing three immunoglobulin-like disulfide loops. Intermediate grades of astrocytic tumors exhibited a gradual loss of FGFR-2 and a shift in expression from FGFR-1 alpha to FGFR-1 beta as they progressed from benign to malignant phenotype. These results suggest that differential expression and alternative splicing of FGFRs may be critical in the malignant progression of astrocytic tumors.
authors.affiliation: Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: F
authors.initials: F
authors.lastname: Yamaguchi
authors.forename: H
authors.initials: H
authors.lastname: Saya
authors.forename: J M
authors.initials: JM
authors.lastname: Bruner
authors.forename: R S
authors.initials: RS
authors.lastname: Morrison
mesh_terms: D017398:Alternative Splicing / Q000235:genetics; D001254:Astrocytoma / Q000235:genetics* / Q000378:metabolism; D001483:Base Sequence; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D017931:DNA Primers / Q000235:genetics; D018076:DNA, Complementary / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D005333:Fetus / Q000378:metabolism; D000091344:Filaggrin Proteins; D015870:Gene Expression; D006801:Humans; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics*
chemical_list: D017931:DNA Primers; D018076:DNA, Complementary; D004273:DNA, Neoplasm; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D017468:Receptors, Fibroblast Growth Factor